The author discusses the impact of the appointment of Dr. Scott Gottlieb as commissioner of the U.S. Food and Drug Administration (FDA) on laboratories. Topics covered include Gottlieb's success as a venture capitalist and financial relationships with large pharmaceutical companies, and his aim of creating a faster-track for drug approval.